Revvity Signals Software has unveiled Signals One, a comprehensive platform designed to integrate data management across the entire drug discovery process. The unified system supports the complete ‘Design-Make-Test-Decide’ research and development lifecycle, with advanced capabilities aimed at tackling previously ‘undruggable’ targets through standardised, AI-ready data workflows.

Signals One was officially introduced at the Bio-IT World Conference & Expo, early April in Boston, Massachusetts.

Platform addresses growing complexity in drug modalities research

The Signals One platform represents an evolution of Revvity’s existing research portfolio, now consolidated into a unified solution that addresses the increasing complexity faced by pharmaceutical researchers. By delivering sophisticated data processing workflows encompassing common analytical tasks – including in vitro curve fitting, in vivo data analysis, and group comparisons – the platform enables more efficient collaboration across multidisciplinary teams.

“With the Signals One platform, we are striving to support scientists across every step of the R&D lifecycle,” said Kevin Willoe, president of Revvity Signals Software. “This solution empowers researchers to develop more targeted, effective therapies with fewer side effects, helping scientists tackle previously ‘undruggable’ targets. The platform enables researchers to quickly eliminate ineffective options and move promising therapies toward clinical trials.”

AI enhancements planned for future development

Revvity has announced plans to enhance the platform with additional AI capabilities, including semantic search functionality, summarisation assistants, and automated protocol writing tools. These features will
be implemented while maintaining robust protections for sensitive intellectual property.

The platform ensures that assay data is standardised and AI-ready, allowing researchers to uncover hidden relationships and insights through advanced analytical tools – a critical capability for modern drug discovery programmes working with complex biological targets.

For more information, visit: www.revvity.com/signals-one

Digital issue: Please click here for more information